Mitochondrial Peptides is a recurring topic in our peptide coverage. This hub collects every article tagged Mitochondrial Peptides, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical, evidence-first ranking of the peptides marketed for mitochondrial dysfunction — elamipretide (SS-31), MOTS-c, humanin and the SHLP family. Only one has any human bioenergetic data, and even that was acute and reversible.
A clinical, evidence-first review of the peptides marketed for long COVID (PASC) fatigue — thymosin alpha-1, elamipretide (SS-31), aviptadil and BPC-157. The blunt headline: no peptide has a positive long-COVID trial.
A clinical, evidence-first review of the peptides marketed for fatigue and low energy — elamipretide (SS-31), thymosin alpha-1, MOTS-c, CJC-1295 and ipamorelin. The blunt headline: no peptide has a positive fatigue RCT in healthy people.
An evidence-graded review of the peptides marketed for endurance and aerobic performance — elamipretide (SS-31), MOTS-c and AOD-9604. The honest 2026 verdict: no peptide is proven to raise VO₂max or race performance in healthy humans, the category is preclinical-dominant, and MOTS-c is WADA-banned at all times.
A clinical, evidence-first look at the peptides marketed for ME/CFS — thymosin alpha-1, elamipretide (SS-31), MOTS-c and cerebrolysin. The honest headline: no peptide has a completed CFS efficacy trial.
A clinical monograph on SS-31 / elamipretide (Forzinity) — the cardiolipin-binding, mitochondria-targeted tetrapeptide. First FDA-approved for Barth syndrome in 2025, yet negative on every other large trial's primary endpoint.
A clinical monograph on SS-20 — the Szeto-Schiller mitochondria-targeting tetrapeptide that protects mitochondria without antioxidant chemistry. Deep preclinical data, no human trials, and unapproved research-only status in 2026.
Mitochondrial Peptides is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Mitochondrial Peptides, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.